2020 PLATFORMS

  • Disease Assessment and Management (DAM)
  • Disease Modifying Therapies (DMT)
  • Psychosocial: Cognition (PSY)
  • Rehabilitation (RHI)

DISEASE ASSESSMENT AND MANAGEMENT

ID: DAM01
International Registry Tracking Pregnancy Outcomes in Women Treated with Dimethyl Fumarate

Maria Houtchens,1 Kerstin Hellwig,2 David Rog,3 Christopher McGuigan,4 Denise R. Bruen,5 Kun Chen,6 Xiaomei Peng,6 Cynthia C. Jones6
1Brigham and Women’s Hospital, Boston, MA; 2University of Bochum, Neurological Clinic, Bochum, Germany; 3Manchester Centre for Clinical Neurosciences, Salford, United Kingdom; 4Department of Neurology, St. Vincent’s University Hospital, Dublin, Ireland; 5Department of Neuroscience, University of Virginia Health,  Charlottesville, VA; 6Biogen, Cambridge, MA

VIEW THE ABSTRACT
ID: DAM02
Menarche and Relapses in Girls with Pediatric Multiple Sclerosis

Kristen M. Krysko,1 Michael Waltz,2 Tanuja Chitnis,3 Bianca Weinstock-Guttman,4 Greg Aaen,5 Leslie Benson,6 Mark Gorman,6 Yolanda Harris,7 Lauren B. Krupp,8 Timothy Lotze,9 Soe Mar,10 Manikum Moodley,11 Jayne Ness,12 Mary Rensel,13 Moses Rodriguez,14 John Rose,15 Alice Rutatangwa,1 Teri Schreiner,16 Emmanuelle Waubant,1 T. Charles Casper,2 Jennifer S. Graves17,18
1Neurology, University of California San Francisco, San Francisco, CA; 2Pediatrics, University of Utah, Salt Lake City, UT; 3Pediatric Neurology, Massachusetts General Hospital, Boston, MA; 4Neurology, State University of New York at Buffalo, Buffalo, NY; 5Pediatrics, Loma Linda University, San Bernardino, CA; 6Neurology, Boston Children’s Hospital, Boston, MA; 7Nursing, University of Alabama at Birmingham, Birmingham, AL; 8Neurology, NYU Langone Medical Center, New York, NY; 9Neurology, Texas Children’s Hospital, Houston, TX; 10Neurology, Washington University in Saint Louis, St. Louis, MO; 11Pediatrics and Neurology, Dell Children’s Hospital, University of Texas, Austin,TX; 12Pediatrics, University of Alabama at Birmingham, Birmingham, AL; 13Neurology, Cleveland Clinic, Cleveland, OH; 14Neurology, Mayo Clinic, Rochester, MN; 15Neurology, University of Utah, Salt Lake City, UT; 16Neurology and Pediatrics, University of Colorado, Aurora, CO; 17Neurosciences, University of California San Diego, San Diego, CA; 18Neurology, University of California San Diego, La Jolla, CA

VIEW THE ABSTRACT
ID: DAM03
Complexity of Aging with Multiple Sclerosis: Graceful Concessions or Kicking and Screaming?
Emma V. Richardson, Robert W. Motl
Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL
VIEW THE ABSTRACT
ID: DAM04
Serum Glial Fibrillary Acidic Protein Is Elevated in a Subset of Neuromyelitis Optica Patients and Associated with Increased Risk of Attacks
Hans-Peter Hartung,1 Orhan Aktas,2 Michael A. Smith,3 William Rees,3 Kazuo Fujihara,4 Friedemann Paul,5 Romain Marignier,6 Jeffrey L. Bennett,7 Ho Jin Kim,8 Brian Weinshenker,9 Sean J. Pittock,10 Dean Wingerchuk,11 Gary Cutter,12 Ari Green,13 Maureen A. Mealy,3 Jorn Drappa,3 Gerard Barron,3 Soraya Madani,3 Liangwei Wang,3 Dewei She,3 Daniel Cimbora,3 John N. Ratchford,3 Eliezer Katz,3 Bruce A.C. Cree14
1Department of Neurology, Medical Faculty, Heinrich Heine University, Dusseldorf, Germany; 2Medical Faculty, Heinrich-Heine-University, Dusseldorf, Germany; 3Viela Bio, Gaithersburg, MD; 4Department of Multiple Sclerosis Therapeutics, Southern Tohoku Research Institute for Neuroscience (STRINS), Koriyama, Japan; 5Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charite – Universitatsmedizin Berlin, Berlin, Germany; 6Lyon University Hospital, Lyon, France; 7School of Medicine, University of Colorado, Aurora, CO; 8Research Institute and Hospital, National Cancer Center, Goyang, Korea, Republic of (South); 9Neurology, Mayo Clinic, Rochester, MN; 10Mayo Clinic, Rochester, MN; 11Neurology, Mayo Clinic Arizona, Scottsdale, AZ; 12Biostatistics, University of Alabama at Birmingham, Birmingham, AL; 13Department of Neurology and Department of Ophthalmology, UCSF Weill Institute for Neurosciences, San Francisco, CA; 14Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA
VIEW THE ABSTRACT
ID: DAM05
Machine Learning Algorithms Applied to Visual Metrics to Classify Demyelinating Disease Diagnosis in Children
Beyza Ciftci,1 Can Kavaklioglu,2 Lauren Erdman,1 Anna Goldenberg,3,4,5,6 Tara Berenbaum,7 Tara Feltham,7 Fiona Costello,8 Jean Mah,9 Arun Reginald,10 Brenda Banwell,11 Giulia Longoni,12 E. Ann Yeh12
1Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada; 2Department of Mechanical and Industrial Engineering, Ryerson University, Toronto, ON, Canada; 3Genetics and Genome Biology Lab, The Hospital for Sick Children, Toronto, ON, Canada; 4Department of Computer Science, University of Toronto, Toronto, ON, Canada; 5Vector Institute, Toronto, ON, Canada; 6CIFAR, Toronto, ON, Canada; 7Department of Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON, Canada; 8Departments of Clinical Neurosciences and Surgery, University of Calgary, Calgary, AB, Canada; 9Department of Pediatrics, University of Calgary, Calgary, AB, Canada; 10Ophthalmology and Vision Sciences, The Hospital for Sick Children, Toronto, ON, Canada; 11Neurology, The Children’s Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 12Department of Paediatrics, Division of Neurology, The Hospital for Sick Children, Toronto, ON, Canada
VIEW THE ABSTRACT
ID: DAM06
Updated Recommendations for a Standardized Magnetic Resonance Imaging Protocol for Multiple Sclerosis
Anthony Traboulsee,1 David Li,1 Brenda Banwell,2 Frederik Barkhof,3 Kathleen Costello,4 Peter Damiri,5 Scott D. Newsome,6 Jiwon Oh,7 Friedemann Paul,8 Daniel S. Reich,9 Mitchell T. Wallin,10 Jerry S. Wolinsky,11 June Halper,12 Sarah A. Morrow,13 Wim Van Hecke,14 Laura Barlow,15 Jason Shewchuk,16 Russell Shinohara,17 Amy Verrinder,18 Micki Maes,18 Patrick Quarterman,19 Kim van de Ven,20 Shivraman Giri,21 Lori Saslow,22 CMSC MRI Guidelines Working Group 1The University of British Columbia, Vancouver, BC, Canada; 2Neurology, The Children’s Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 3Institutes of Neurology and Healthcare Engineering, University College London, London, United Kingdom; 4National MS Society, New York, NY; 5Multiple Sclerosis Association of America, Cherry Hill, NJ; 6Neurology, Johns Hopkins University School of Medicine, Baltimore, MD; 7University of Toronto, Toronto, ON, Canada; 8Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charite – Universitatsmedizin Berlin, Berlin, Germany; 9Translational Neuroradiology Unit, National Institute of Neurological Disorders and Stroke, Bethesda, MD; 10Washington, DC, VA Medical Center, MS Center of Excellence, Washington, DC; 11University of Texas Health Science Center at Houston (UTHealth), Houston, TX; 12CEO-CMSC, Hackensack, NJ; 13Western University, London, ON, Canada; 14Icometrix, Leuven, Belgium; 15UBC MRI Research Centre, University of British Columbia, Vancouver, BC, Canada; 16Vancouver General Hospital, Vancouver, BC, Canada; 17University of Pennsylvania, Philadelphia, PA; 18Cortechs Labs, Inc, San Diego, CA; 19GE Healthcare, New York, NY; 20Philips Healthcare, Eindhoven, Netherlands; 21Siemens Healthineers, Boston, MA; 22Consortium of Multiple Sclerosis Centers, Hackensack, NJ
VIEW THE ABSTRACT

DISEASE-MODIFYING THERAPY

ID: DMT01
Comparative Effectiveness of Switching from Natalizumab to a Moderate- Versus High-Efficacy Disease-Modifying Therapy in Clinical Practice

Carrie M. Hersh,1 Haleigh Harris,2 Devon Conway,3 Le H. Hua1 1Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV; 2Las Vegas, NV; 3Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland, OH

VIEW THE ABSTRACT
ID: DMT02
Yearly Efficacy and Safety Outcomes Over 4 Years After Last Alemtuzumab Course in Pooled CAREMS I and II Patients by Number of Additional Courses Received Through Year 9
Regina Berkovich,1,2 Raed Alroughani,3 Ann D. Bass,4 Aaron L. Boster,5 Giancarlo Comi,6 Ho Jin Kim,7 Volker Limmroth,8 Jan Lycke,9 Richard A.L. Macdonell,10 Sven Schippling,11 Basil Sharrack,12 Mar Tintoré,13 Anthony Traboulsee,14 Patrick Vermersch,15 Heinz Wiendl,16 Tjalf Ziemssen,17 Nadia Daizadeh,18 Alan Jacobs,18 Elizabeth M. Poole,18 Barry A. Singer,19 on behalf of the CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators
1Keck School of Medicine, University of Southern California, Los Angeles, CA; 2Regina Berkovich, MD, PhD, Inc, West Hollywood, CA; 3Amiri Hospital, Sharq, Kuwait; 4Neurology Center of San Antonio, San Antonio, TX; 5Boster MS Center, Columbus, OH; 6University Vita-Salute San Raffaele, Milan, Italy; 7Research Institute and Hospital, National Cancer Center, Goyang, Korea, Republic of (South); 8Klinik für Neurologie und Palliativmedizin, Cologne, Germany; 9Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden; 10Austin Health and Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia; 11University Hospital Zürich and University of Zürich, Zürich, Switzerland; 12NIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals, University of Sheffield, Sheffield, United Kingdom; 13University Hospital Vall d’Hebron, Barcelona, Spain; 14The University of British Columbia, Vancouver, BC, Canada; 15University of Lille, INSERM U995, CHU Lille, Lille, France; 16Department of Neurology, University of Münster, Münster, Germany; 17Center for Clinical Neuroscience, Carl Gustav Carus University Hospital, Dresden, Germany; 18Sanofi, Cambridge, MA; 19The MS Center for Innovations in Care, Missouri Baptist Medical Center, St Louis, MO
VIEW THE ABSTRACT
ID: DMT03
Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients with Relapsing Multiple Sclerosis: Phase 3 ASCLEPIOS I and II Trials

Anne H. Cross,1 Ludwig Kappos,2 Amit Bar-Or,3 Jeffrey A. Cohen,4 Giancarlo Comi,5 Jorge Correale,6 Patricia K. Coyle,7 Jerome de Seze,8 David Leppert,9 Xavier Montalban,10,11 Krzysztof W. Selmaj,12 Heinz Wiendl,13 Cecile Kerloeguen,14 Roman Willi,14 Bingbing Li,15 Algirdas Kakarieka,14 Davorka Tomic,14 Alexandra Goodyear,15 Ratnakar Pingili,15 Dieter A. Haering,14 Krishnan Ramanathan,14 Martin Merschhemke,14 Stephen L. Hauser16 1Department of Neurology, Division of Neuroimmunology, Washington University School of Medicine, St Louis, MO; 2Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital of Basel, Basel, Switzerland; 3Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 4Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH; 5University Vita-Salute San Raffaele, Milan, Italy; 6Institute for Neurological Research Dr. Raul Carrea, Buenos Aires, Argentina; 7Stony Brook University, Stony Brook, NY; 8University Hospital of Strasbourg, Strasbourg, France; 9Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland; 10Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Barcelona, Spain; 11St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada; 12Department of Neurology, Medical Academy of Lodz, Lodz, Poland; 13Department of Neurology, University of Münster, Münster, Germany; 14Novartis Pharma AG, Basel, Switzerland; 15Novartis Pharmaceuticals Corporation, East Hanover, NJ; 16University of California, San Francisco, San Francisco, CA

VIEW THE ABSTRACT
ID: DMT04
Treatment-Emergent Adverse Events Occurring Early in the Treatment Course of Cladribine Tablets in Two Phase 3 Trials in Multiple Sclerosis
Jiwon Oh,1 Bryan Walker,2 Gavin Giovannoni,3 Dominic Jack,4 Fernando Dangond,5 Axel Nolting,4 Julie Aldridge,5 Lori Lebson,6 Thomas P. Leist7
1Keenan Research Center for Biomedical Sciences, St. Michaels Hospital, Toronto, ON, Canada; 2Neurological Department, Duke University School of Medicine, Durham, NC; 3Blizard Institute of Cell and Molecular Science, London, United Kingdom; 4Merck KGaA, Darmstadt, Germany; 5EMD Serono, Inc, Billerica, MA; 6EMD Serono, Inc, Rockland, MA; 7Jefferson University Hospital, Philadelphia, PA
VIEW THE ABSTRACT

PSYCHOSOCIAL: COGNITION

ID: PSY01
A Mindfulness Group Intervention in Newly Diagnosed Persons with Multiple Sclerosis: A Pilot Study
Sarah A. Morrow,1 Nancy Vording,1 Jordan Ward,1 Courtney S. Casserly,2 Heather Rosehart,3 Arlene Macdougall4
1Clinical Neurological Sciences, London Health Sciences Centre, London, ON, Canada; 2Clinical Neurological Sciences, Western University, London, ON, Canada; 3Clinical Neurological Sciences, University of Western Ontario, London Health Sciences Center, London, ON, Canada; 4Psychiatry and Epidemiology & Biostatistics, St. Joseph’s Health Care, Parkwood Institute, London, ON, Canada
VIEW THE ABSTRACT
ID: PSY02
Effects of Weekly Participation in a Wellness Program on Self-Reported Measures for People Living with Multiple Sclerosis: A 3-Year Analysis

Brian Hutchinson,1 John Schafer,2 Lacey Sayre,3 Tiffany Malone3 1Multiple Sclerosis Achievement Center, Dignity Health, Sacramento, CA; 2Mercy MS Center, Carmichael, CA; 3Multiple Sclerosis Achievement Center, Dignity Health, Citrus Heights, CA

VIEW THE ABSTRACT
ID: PSY03
Examining Multilevel Environmental Correlates of Physical Activity Among Older Adults with Multiple Sclerosis
Stephanie L. Silveira, Jessica F. Baird, Robert W. Motl
Physical Therapy, University of Alabama at Birmingham, Birmingham, AL
VIEW THE ABSTRACT
ID: PSY04
Effect of Nabiximols Cannabinoid Oromucosal Spray on Depressive Symptoms, Suicidality, and Cognition in Patients with Multiple Sclerosis
John DeLuca,1 Dawn Langdon,2 Joris Berwaerts,3 Joanne Wagner3
1Kessler Foundation, West Orange, NJ; 2Department of Psychology, Clinical, Health and Social Psychology, Royal Holloway, University of London, Egham, United Kingdom; 3Greenwich Biosciences, Inc, Carlsbad, CA
VIEW THE ABSTRACT
ID: PSY06
Multiple Sclerosis Management: Predicting Disease Trajectory of Multiple Sclerosis on Multidimensional Data Including Digital Cognitive Assessments and Patient-Reported Outcomes Using Machine Learning Techniques
Mark Gudesblatt,1 Jared Srinivasan,1 Olivia Kaczmarek,1 Daniel Kantor,2 Daniel Golan,3 Myassar Zarif,1 Barbara Bumstead,1 Marijean Buhse,1 Lori Fafard,1 Timothy Fratto,4 Jeffrey Wilken,4 Cynthia Sullivan,5 Glen Doniger6
1South Shore Neurologic Associates, Patchogue, NY; 2Florida Atlantic University, Boca Raton, FL; 3Rapparport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; 4Washington Neuropsychology Research Group, Washington, DC; 5Nursing, State University of New York at Stony Brook, Stony Brook, NY; 6NeuroTrax Corp, Modiin, Israel
VIEW THE ABSTRACT

REHABILITATION

ID: RHI01
Significant Structural Neuroplasticity Changes Can Follow Physical Behavioral Change Therapy for Multiple Sclerosis

Victor W. Mark,1 Brent M. Womble,2 Gitendra Uswatte,2 David M. Morris,3 Mary H. Bowman,2 Staci McKay,2 Edward Taub2
1Physical Medicine and Rehabilitation, University of Alabama at Birmingham (UAB), Birmingham, AL; 2Psychology, UAB, Birmingham, AL; 3Physical Therapy, UAB, Birmingham, AL

VIEW THE ABSTRACT
ID: RHI02
A New Look at the Symbol Digit Modalities Test in Multiple Sclerosis and Disabilities
Yilan Liu,1 Victor W. Mark,2 Sean Bowman,1 Razeen M. Mahmud,1 Janet Niemeier,1 Stacey S. Cofield3
1University of Alabama at Birmingham (UAB), Birmingham, AL; 2Physical Medicine and Rehabilitation, UAB, Birmingham, AL; 3Biostatistics, UAB, Birmingham, AL
VIEW THE ABSTRACT
ID: RHI03
Creating a Yoga Program as Part of a Comprehensive Multiple Sclerosis Care Model
Sandra Chapman, Ruth Almen, Carrie M. Hersh, Le H. Hua
Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV
VIEW THE ABSTRACT
ID: RHI04
Feasibility of “Sit Less, Move More”: An Intervention for Reducing Sedentary Behavior Among African Americans with Multiple Sclerosis
Jessica F. Baird,1 Jeffer E. Sasaki,2 Brian M. Sandroff,1 Gary Cutter,3 Robert W. Motl1
1Physical Therapy, University of Alabama at Birmingham, Birmingham, AL; 2Department of Sports Sciences, Universidade Federal do Triangulo Mineiro, Bairro Tutunas, Brazil; 3Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, AL
VIEW THE ABSTRACT
ID: RHI05
The Effect of Aerobic Fitness on Physical and Cognitive Function and Brain Volume in Older Adults with Multiple Sclerosis
Jessica F. Baird,1 Marcas Bamman,2 Cynthia Brown,2 John R. Rinker,3 Robert W. Motl1
1Physical Therapy, University of Alabama at Birmingham (UAB), Birmingham, AL; 2UAB, Birmingham, AL; 3Neurology, UAB, Birmingham, AL
VIEW THE ABSTRACT
ID: RHI06
Functional Electrical Stimulation Cycling Exercise Reduces Lower Limb Strength Asymmetry in Persons with Multiple Sclerosis
John W. Farrell III,1 Thomas Edwards,2 Robert W. Motl,3 Lara A. Pilutti1
1Interdisciplinary School of Health Sciences, University of Ottawa, Ottawa, ON, Canada; 2School of Human Kinetics, University of Ottawa, Ottawa, ON, Canada; 3Physical Therapy, University of Alabama at Birmingham, Birmingham, AL
VIEW THE ABSTRACT